ClinicalTrials.gg
CompletedNCT03823287Updated Jul 23, 2025Results posted

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

A Phase 3 interventional study of Faricimab and Aflibercept in Wet Macular Degeneration, sponsored by Hoffmann-La Roche. Completed at 161 sites in 15 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
671
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Wet Macular Degeneration with a site in United States — 7 open to participants now, 14 under way, 7 of them phase 3. Wet Macular Degeneration · United States.

Enrollment
7th of 45
671 · median 91
Started
2019
with 9 others
Phase 3
13 of 49
1 open now
Registered
21st of 49
by date
Lead sponsor
2 of 49
Hoffmann-La Roche

Among the 49 studies in Wet Macular Degeneration with a site in United States, this one is the 7th largest by enrollment of the 45 interventional ones that give a count, is one of 10 that started in 2019, is one of 13 in phase 3, and was the 21st registered.

Wet Macular Degeneration

93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.

Browse Wet Macular Degeneration studies →

Open to participants now

7 of the 49 studies in Wet Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Wet Macular Degeneration studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Wet Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).

03

Conditions studied

  • Wet Macular Degeneration

Keywords

  • AMD
  • nAMD
  • neovascular age-related macular degeneration
  • choroidal neovascularization secondary to age-related macular degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treatment-naïve choroidal neovascularization (CNV) secondary to age-related macular degeneration (nAMD) in the study eye
  • Ability to comply with the study protocol, in the investigator's judgment
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use acceptable measures that result in failure rate \<1% per year during the treatment period and for at least 3 months after the final dose of study treatment
  • Other protocol-specified inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled blood pressure, defined as systolic blood pressure >180 millimeters of mercury (mmHg) and/or diastolic blood pressure >100 mmHg while a patient is at rest on Day 1
  • Pregnancy or breastfeeding, or intention to become pregnant during the study
  • CNV due to causes other than AMD in the study eye
  • Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid in the study eye
  • Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the study
  • Uncontrolled glaucoma in the study eye
  • Any prior or concomitant treatment for CNV or vitreomacular-interface abnormalities in the study eye
  • Prior IVT administration of faricimab in either eye
  • History of idiopathic or -associated uveitis in either eye
  • Active ocular inflammation or suspected or active ocular or periocular infection in either eye
  • Other protocol-specified exclusion criteria may apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
671 participants (actual)

Study arms

  • Experimental
    Faricimab

    Drug: Faricimab · Procedure: Sham Procedure

  • Active comparator
    Aflibercept

    Drug: Aflibercept · Procedure: Sham Procedure

Interventions

  • Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.

    Also known as: VABYSMO™, RO6867461, RG7716

  • Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).

    Also known as: Eylea

  • ProcedureSham Procedure

    The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI.

    Time frame: From Baseline through Week 48

Secondary outcomes

  1. Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI.

    Time frame: From Baseline through Week 60

  2. Change From Baseline in BCVA in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  3. Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, average of Weeks 40, 44, and 48

  4. Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, average of Weeks 52, 56, and 60

  5. Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  6. Percentage of Participants Gaining ≥10 Letters From the Baseline BCVA in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  7. Percentage of Participants Gaining ≥5 Letters From the Baseline BCVA in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  8. Percentage of Participants Gaining ≥0 Letters From the Baseline BCVA in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  9. Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, average of Weeks 40, 44, and 48

  10. Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, average of Weeks 52, 56, and 60

  11. Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  12. Percentage of Participants Avoiding a Loss of ≥10 Letters From the Baseline BCVA in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  13. Percentage of Participants Avoiding a Loss of ≥5 Letters From the Baseline BCVA in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  14. Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, average of Weeks 40, 44, and 48

  15. Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  16. Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\<69 letters vs. ≥69 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, average of Weeks 40, 44, and 48

  17. Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\<69 letters vs. ≥69 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  18. Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, average of Weeks 40, 44, and 48

  19. Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  20. Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 48

    Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 48. The treatment interval at a given visit is defined as the treatment interval decision followed at that visit. The 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Week 48

  21. Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 60

    Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 60. The treatment interval at a given visit is defined as the treatment interval decision followed at that visit. The 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Week 60

  22. Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 112

    Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 112. Treatment interval at a given visit is defined as the treatment interval decision followed at that visit. Treatment interval at Week 112 is calculated using data recorded at Week 108. The 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Weeks 108 and 112

  23. Number of Study Drug Injections Received in the Study Eye Through Week 48

    Time frame: From Baseline through Week 48

  24. Number of Study Drug Injections Received in the Study Eye Through Week 60

    Time frame: From Baseline through Week 60

  25. Number of Study Drug Injections Received in the Study Eye Through Week 108

    Time frame: From Baseline through Week 108

  26. Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 40, 44, and 48

    Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (\<33 letters and ≥33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: From Baseline through Week 48

  27. Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 52, 56, and 60

    Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (\<33 letters and ≥33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: From Baseline through Week 60

  28. Change From Baseline in Central Subfield Thickness in the Study Eye Over Time

    Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (\<33 letters and ≥33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

  29. Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time

    Intraretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 millimetre \[mm\]). The weighted estimates of the percentage of participants with absence of intraretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112

  30. Percentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time

    Subretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants with absence of subretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112

  31. Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time

    Intraretinal fluid and subretinal fluid were measured using optical coherence tomography (OCT) in the central subfield (center 1 millimetre \[mm\]). The weighted estimates of the percentage of participants with absence of intraretinal and subretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112

  32. Percentage of Participants With Absence of Pigment Epithelial Detachment in the Study Eye Over Time

    Pigment epithelial detachment was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants with absence of pigment epithelial detachment were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112

  33. Percentage of Participants With Absence of Intraretinal Cysts in the Study Eye Over Time

    Time frame: Up to 112 weeks

  34. Change From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 48

    The total area of the choroidal neovascularization lesion in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

    Time frame: Baseline and Week 48

  35. Change From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 112

    The total area of the choroidal neovascularization lesion in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

    Time frame: Baseline and Week 112

  36. Change From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 48

    The total area of choroidal neovascularization leakage in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

    Time frame: Baseline and Week 48

  37. Change From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 112

    The total area of choroidal neovascularization leakage in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

    Time frame: Baseline and Week 112

  38. Percentage of Participants With at Least One Adverse Event

    This analysis of adverse events (AEs) includes both ocular and non-ocular (systemic) AEs. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. AEs of special interest included the following: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law; Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

    Time frame: From first dose of study drug through end of study (up to 112 weeks)

  39. Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye

    This analysis of adverse events (AEs) only includes ocular AEs, which are categorized as having occurred either in the study eye or the fellow eye. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

    Time frame: From first dose of study drug through end of study (up to 112 weeks)

  40. Percentage of Participants With at Least One Non-Ocular Adverse Event

    This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

    Time frame: From first dose of study drug through end of study (up to 112 weeks)

  41. Plasma Concentration of Faricimab Over Time

    Faricimab concentration in plasma was determined using a validated immunoassay method.

    Time frame: Pre-dose at Baseline, Weeks 4, 16, 20, 48, 76, and 112

  42. Percentage of Participants Who Tested Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study

    Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The percentage of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period.

    Time frame: Pre-dose at Baseline, Weeks 4, 20, 48, 76, and 112

07

Results

Posted May 4, 2022

Participant flow

Participant flow — Overall Study
MilestoneArm A: FaricimabArm B: Aflibercept
Started334337
Received at least one dose of study drug333336
Completed up to week 48319323
Completed274291
Not completed6046
Withdrew: Withdrawal by subject2517
Withdrew: Death137
Withdrew: Lost to follow-up78
Withdrew: Adverse event68
Withdrew: Physician decision52
Withdrew: Lack of efficacy20
Withdrew: Other24

Outcome measures

PrimaryChange From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI.

Time frame:
From Baseline through Week 48
Reported as:
Mean · ETDRS Letters
Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48
ETDRS LettersArm A: FaricimabArm B: Aflibercept
Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 485.8 (4.6 to 7.1)5.1 (3.9 to 6.4)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Adjusted mean difference: 0.7 · 95% CI -1.1 to 2.5The treatment difference in adjusted means of change from baseline BCVA is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept. MMRM adjustments are listed in the outcome measure description.
SecondaryChange From Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI.

Time frame:
From Baseline through Week 60
Reported as:
Mean · ETDRS Letters
Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60
ETDRS LettersArm A: FaricimabArm B: Aflibercept
Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 605.4 (4.0 to 6.8)4.6 (3.3 to 6.0)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Adjusted mean difference: 0.7 · 95% CI -1.2 to 2.7The treatment difference in adjusted means of change from baseline BCVA is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept. MMRM adjustments are listed in the outcome measure description.
SecondaryChange From Baseline in BCVA in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Mean · ETDRS Letters
Change From Baseline in BCVA in the Study Eye Over Time
ETDRS LettersArm A: FaricimabArm B: Aflibercept
Week 44.0 (3.2 to 4.8)3.6 (2.8 to 4.4)
Week 85.5 (4.6 to 6.4)4.5 (3.6 to 5.4)
Week 126.4 (5.5 to 7.4)5.3 (4.4 to 6.2)
Week 166.8 (5.8 to 7.8)5.2 (4.2 to 6.2)
Week 206.6 (5.5 to 7.6)4.9 (3.9 to 6.0)
Week 246.4 (5.2 to 7.5)5.1 (4.0 to 6.3)
Week 286.2 (5.1 to 7.3)5.6 (4.5 to 6.7)
Week 326.2 (4.9 to 7.4)5.1 (3.8 to 6.3)
Week 366.5 (5.3 to 7.7)5.5 (4.3 to 6.7)
Week 406.1 (4.9 to 7.4)5.1 (3.9 to 6.4)
Week 445.8 (4.5 to 7.1)5.1 (3.8 to 6.4)
Week 485.5 (4.1 to 6.9)5.2 (3.8 to 6.5)
Week 525.6 (4.2 to 7.1)4.5 (3.1 to 5.9)
Week 565.5 (4.1 to 6.9)4.7 (3.3 to 6.1)
Week 604.9 (3.5 to 6.3)4.7 (3.2 to 6.1)
Week 645.5 (4.1 to 6.9)4.8 (3.5 to 6.2)
Week 685.3 (3.9 to 6.8)4.6 (3.2 to 6.1)
Week 724.8 (3.3 to 6.3)4.0 (2.5 to 5.4)
Week 764.7 (3.1 to 6.2)4.4 (2.9 to 5.9)
Week 804.6 (3.1 to 6.1)3.5 (2.0 to 5.1)
Week 844.5 (3.0 to 6.1)3.5 (2.0 to 5.1)
Week 884.3 (2.7 to 5.9)3.7 (2.1 to 5.2)
Week 924.2 (2.6 to 5.9)3.7 (2.1 to 5.3)
Week 964.2 (2.5 to 5.8)3.7 (2.0 to 5.3)
Week 1004.3 (2.7 to 5.9)3.6 (2.0 to 5.2)
Week 1044.1 (2.5 to 5.8)3.6 (2.0 to 5.2)
Week 1083.6 (1.8 to 5.3)3.2 (1.5 to 4.9)
Week 1123.5 (1.8 to 5.2)3.1 (1.4 to 4.8)
SecondaryPercentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, average of Weeks 40, 44, and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Gaining ≥15 Letters20.0 (15.6 to 24.4)15.7 (11.9 to 19.6)
Gaining ≥10 Letters37.1 (31.7 to 42.4)31.7 (26.7 to 36.8)
Gaining ≥5 Letters59.2 (53.7 to 64.7)58.0 (52.6 to 63.5)
Gaining ≥0 Letters75.6 (70.8 to 80.3)76.8 (72.1 to 81.4)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: 4.3 · 95% CI -1.6 to 10.1The treatment difference in CMH weighted percentage of participants gaining ≥15 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: 5.4 · 95% CI -2.0 to 12.7The treatment difference in CMH weighted percentage of participants gaining ≥10 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: 1.2 · 95% CI -6.6 to 8.9The treatment difference in CMH weighted percentage of participants gaining ≥5 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: -1.2 · 95% CI -7.9 to 5.4The treatment difference in CMH weighted percentage of participants gaining ≥0 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
SecondaryPercentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, average of Weeks 52, 56, and 60
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 6019.2 (15.0 to 23.5)16.6 (12.5 to 20.6)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: 2.7 · 95% CI -3.2 to 8.5The treatment difference in CMH weighted percentage of participants gaining ≥15 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
SecondaryPercentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 410.1 (6.9 to 13.2)6.3 (3.8 to 8.8)
Week 813.7 (10.1 to 17.3)8.1 (5.3 to 10.9)
Week 1216.7 (12.8 to 20.5)10.1 (7.0 to 13.1)
Week 1617.7 (13.7 to 21.6)13.4 (10.0 to 16.9)
Week 2019.1 (14.9 to 23.2)12.7 (9.1 to 16.2)
Week 2422.1 (17.4 to 26.7)13.3 (9.6 to 17.0)
Week 2820.8 (16.4 to 25.2)16.2 (12.1 to 20.3)
Week 3221.6 (17.0 to 26.1)15.1 (11.3 to 18.9)
Week 3621.4 (16.8 to 26.0)15.7 (11.8 to 19.6)
Week 4022.1 (17.5 to 26.7)15.6 (11.7 to 19.5)
Week 4422.2 (17.5 to 26.8)17.4 (13.2 to 21.6)
Week 4821.2 (16.7 to 25.8)19.7 (15.3 to 24.0)
Week 5222.5 (17.8 to 27.2)18.3 (14.0 to 22.7)
Week 5623.1 (18.4 to 27.8)18.8 (14.6 to 23.0)
Week 6021.3 (16.7 to 25.9)17.4 (13.3 to 21.5)
Week 6420.3 (15.6 to 25.0)20.1 (15.7 to 24.6)
Week 6823.2 (18.3 to 28.1)18.5 (14.1 to 22.8)
Week 7221.1 (16.5 to 25.8)17.4 (13.1 to 21.6)
Week 7622.9 (18.0 to 27.8)18.0 (13.7 to 22.3)
Week 8019.7 (14.9 to 24.5)18.8 (14.4 to 23.2)
Week 8421.1 (16.4 to 25.9)18.3 (14.0 to 22.5)
Week 8824.6 (19.7 to 29.6)18.6 (14.3 to 23.0)
Week 9221.4 (16.5 to 26.3)19.5 (14.9 to 24.0)
Week 9623.0 (18.1 to 27.9)20.2 (15.7 to 24.6)
Week 10021.5 (16.7 to 26.3)18.2 (13.9 to 22.5)
Week 10422.9 (17.9 to 27.8)18.6 (14.2 to 22.9)
Week 10821.9 (17.0 to 26.7)19.0 (14.6 to 23.4)
Week 11224.0 (19.1 to 29.0)19.2 (14.6 to 23.7)
SecondaryPercentage of Participants Gaining ≥10 Letters From the Baseline BCVA in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥10 Letters From the Baseline BCVA in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 420.1 (16.0 to 24.2)16.0 (12.3 to 19.7)
Week 828.6 (23.9 to 33.3)25.3 (20.9 to 29.8)
Week 1231.4 (26.5 to 36.3)30.3 (25.5 to 35.1)
Week 1636.9 (31.8 to 41.9)31.9 (27.0 to 36.7)
Week 2039.1 (34.0 to 44.2)30.3 (25.4 to 35.2)
Week 2441.4 (36.0 to 46.9)34.0 (28.7 to 39.3)
Week 2838.9 (33.5 to 44.3)34.8 (29.5 to 40.1)
Week 3238.6 (33.2 to 44.0)32.4 (27.2 to 37.7)
Week 3637.1 (31.6 to 42.6)34.0 (28.8 to 39.2)
Week 4036.9 (31.5 to 42.3)33.9 (28.6 to 39.2)
Week 4439.5 (33.9 to 45.0)34.3 (29.0 to 39.7)
Week 4836.8 (31.3 to 42.3)36.8 (31.4 to 42.2)
Week 5238.7 (33.2 to 44.2)37.7 (32.2 to 43.2)
Week 5640.3 (34.8 to 45.8)36.2 (30.8 to 41.6)
Week 6040.1 (34.7 to 45.5)34.8 (29.4 to 40.3)
Week 6437.2 (31.4 to 43.0)36.6 (31.1 to 42.0)
Week 6840.0 (34.3 to 45.7)33.3 (27.8 to 38.7)
Week 7240.1 (34.4 to 45.8)34.3 (28.8 to 39.8)
Week 7639.4 (33.7 to 45.2)33.5 (28.0 to 39.0)
Week 8035.5 (29.8 to 41.2)33.0 (27.7 to 38.4)
Week 8438.2 (32.5 to 43.9)34.3 (28.9 to 39.7)
Week 8838.9 (33.2 to 44.7)33.6 (28.3 to 39.0)
Week 9237.8 (31.9 to 43.7)35.3 (29.7 to 40.8)
Week 9639.6 (33.7 to 45.4)35.8 (30.3 to 41.4)
Week 10038.5 (32.7 to 44.4)36.4 (30.8 to 42.0)
Week 10438.7 (32.9 to 44.6)38.9 (33.3 to 44.5)
Week 10835.1 (29.3 to 40.9)36.6 (30.9 to 42.2)
Week 11239.5 (33.8 to 45.3)34.9 (29.3 to 40.5)
SecondaryPercentage of Participants Gaining ≥5 Letters From the Baseline BCVA in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥5 Letters From the Baseline BCVA in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 447.6 (42.3 to 52.8)45.6 (40.4 to 50.9)
Week 857.8 (52.5 to 63.0)52.3 (47.2 to 57.5)
Week 1261.5 (56.3 to 66.8)55.0 (49.7 to 60.2)
Week 1661.8 (56.5 to 67.0)54.0 (48.7 to 59.3)
Week 2060.2 (54.8 to 65.6)55.5 (50.0 to 60.9)
Week 2463.4 (57.9 to 68.9)53.6 (48.0 to 59.3)
Week 2860.8 (55.3 to 66.3)61.4 (55.8 to 67.0)
Week 3260.5 (55.1 to 65.9)56.4 (50.8 to 62.0)
Week 3660.5 (55.0 to 66.0)58.5 (53.0 to 64.0)
Week 4059.1 (53.6 to 64.6)54.5 (48.9 to 60.2)
Week 4460.3 (54.7 to 65.9)59.0 (53.3 to 64.6)
Week 4859.3 (53.7 to 65.0)58.8 (53.2 to 64.4)
Week 5262.6 (57.0 to 68.1)58.5 (52.8 to 64.1)
Week 5658.6 (53.0 to 64.2)54.4 (48.7 to 60.2)
Week 6060.4 (54.8 to 66.0)57.4 (51.6 to 63.1)
Week 6459.3 (53.5 to 65.2)55.1 (49.3 to 60.9)
Week 6860.4 (54.7 to 66.1)57.0 (51.2 to 62.7)
Week 7259.8 (54.0 to 65.5)52.3 (46.5 to 58.1)
Week 7659.3 (53.5 to 65.1)55.0 (49.1 to 60.9)
Week 8055.2 (49.3 to 61.2)55.5 (49.6 to 61.3)
Week 8458.4 (52.6 to 64.2)55.6 (49.8 to 61.4)
Week 8859.3 (53.5 to 65.1)53.8 (48.0 to 59.6)
Week 9256.8 (50.8 to 62.9)56.0 (50.3 to 61.8)
Week 9658.2 (52.2 to 64.1)57.5 (51.7 to 63.4)
Week 10059.1 (53.2 to 65.1)57.1 (51.2 to 63.0)
Week 10459.8 (54.0 to 65.7)54.8 (48.9 to 60.7)
Week 10853.6 (47.7 to 59.6)54.1 (48.2 to 60.1)
Week 11257.3 (51.4 to 63.2)53.5 (47.6 to 59.5)
SecondaryPercentage of Participants Gaining ≥0 Letters From the Baseline BCVA in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥0 Letters From the Baseline BCVA in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 478.9 (74.5 to 83.2)77.6 (73.3 to 81.9)
Week 880.7 (76.4 to 84.9)78.3 (73.9 to 82.7)
Week 1284.2 (80.3 to 88.1)81.4 (77.3 to 85.6)
Week 1684.8 (80.9 to 88.7)78.8 (74.6 to 83.1)
Week 2080.8 (76.5 to 85.2)79.6 (75.2 to 83.9)
Week 2481.9 (77.5 to 86.3)79.6 (75.1 to 84.1)
Week 2877.8 (73.1 to 82.6)82.3 (77.9 to 86.7)
Week 3278.7 (74.2 to 83.1)76.3 (71.5 to 81.0)
Week 3678.9 (74.3 to 83.5)81.0 (76.6 to 85.4)
Week 4077.1 (72.5 to 81.7)80.7 (76.3 to 85.2)
Week 4477.0 (72.3 to 81.7)78.3 (73.6 to 83.0)
Week 4877.0 (72.2 to 81.8)76.4 (71.5 to 81.3)
Week 5277.4 (72.6 to 82.2)75.7 (70.7 to 80.6)
Week 5676.3 (71.4 to 81.1)78.7 (73.9 to 83.5)
Week 6074.4 (69.3 to 79.5)77.5 (72.6 to 82.3)
Week 6477.7 (72.8 to 82.6)73.7 (68.6 to 78.8)
Week 6874.9 (69.8 to 80.0)77.7 (72.8 to 82.6)
Week 7274.9 (69.9 to 79.8)74.8 (69.8 to 79.8)
Week 7675.7 (70.8 to 80.7)72.0 (66.6 to 77.4)
Week 8075.5 (70.4 to 80.5)74.4 (69.3 to 79.5)
Week 8475.5 (70.5 to 80.5)72.5 (67.3 to 77.7)
Week 8874.8 (69.6 to 80.0)71.7 (66.4 to 76.9)
Week 9275.0 (69.9 to 80.2)70.6 (65.3 to 75.9)
Week 9674.7 (69.6 to 79.9)71.1 (65.7 to 76.5)
Week 10074.6 (69.4 to 79.8)69.7 (64.2 to 75.2)
Week 10473.8 (68.6 to 79.1)71.2 (66.0 to 76.5)
Week 10873.4 (68.2 to 78.7)73.7 (68.4 to 79.0)
Week 11272.8 (67.5 to 78.1)70.9 (65.5 to 76.3)
SecondaryPercentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, average of Weeks 40, 44, and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Avoiding a Loss of ≥15 Letters95.4 (93.0 to 97.7)94.1 (91.5 to 96.7)
Avoiding a Loss of ≥10 Letters91.6 (88.6 to 94.7)92.0 (89.1 to 95.0)
Avoiding a Loss of ≥5 Letters88.0 (84.3 to 91.6)86.8 (83.0 to 90.5)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: 1.3 · 95% CI -2.2 to 4.8The treatment difference in CMH weighted percentage of participants avoiding a loss of ≥15 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: -0.4 · 95% CI -4.6 to 3.9The treatment difference in CMH weighted percentage of participants avoiding a loss of ≥10 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: 1.2 · 95% CI -4.0 to 6.4The treatment difference in CMH weighted percentage of participants avoiding a loss of ≥5 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
SecondaryPercentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, average of Weeks 52, 56, and 60
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 6093.9 (91.3 to 96.5)94.1 (91.4 to 96.8)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: -0.2 · 95% CI -3.9 to 3.6The treatment difference in CMH weighted percentage of participants avoiding a loss of ≥15 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
SecondaryPercentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 497.6 (95.9 to 99.2)99.0 (98.0 to 100.0)
Week 897.6 (96.0 to 99.2)98.7 (97.6 to 99.9)
Week 1298.2 (96.7 to 99.6)97.5 (95.8 to 99.1)
Week 1698.1 (96.7 to 99.6)97.0 (95.3 to 98.8)
Week 2097.4 (95.7 to 99.1)94.9 (92.5 to 97.3)
Week 2497.2 (95.3 to 99.1)97.5 (95.8 to 99.3)
Week 2895.9 (93.8 to 98.1)96.7 (94.6 to 98.8)
Week 3295.4 (93.1 to 97.7)95.7 (93.5 to 98.0)
Week 3695.2 (92.8 to 97.6)95.4 (93.1 to 97.7)
Week 4096.6 (94.5 to 98.6)94.2 (91.6 to 96.8)
Week 4495.7 (93.5 to 98.0)93.9 (91.2 to 96.6)
Week 4894.0 (91.3 to 96.7)93.3 (90.4 to 96.1)
Week 5293.5 (90.8 to 96.2)93.5 (90.7 to 96.3)
Week 5694.7 (92.2 to 97.2)95.0 (92.5 to 97.5)
Week 6093.6 (90.8 to 96.4)92.6 (89.7 to 95.6)
Week 6494.1 (91.3 to 96.9)92.9 (89.9 to 95.9)
Week 6892.6 (89.6 to 95.6)92.9 (89.9 to 95.8)
Week 7293.5 (90.7 to 96.3)91.3 (88.2 to 94.4)
Week 7694.2 (91.6 to 96.8)92.7 (89.8 to 95.7)
Week 8093.6 (90.9 to 96.4)90.7 (87.4 to 93.9)
Week 8492.8 (89.9 to 95.7)91.5 (88.4 to 94.5)
Week 8893.1 (90.3 to 96.0)90.4 (87.2 to 93.7)
Week 9292.1 (89.1 to 95.2)93.2 (90.5 to 95.9)
Week 9691.6 (88.4 to 94.8)88.9 (85.3 to 92.5)
Week 10092.7 (89.8 to 95.6)89.5 (86.0 to 93.0)
Week 10493.2 (90.3 to 96.1)90.7 (87.4 to 93.9)
Week 10892.0 (88.9 to 95.1)89.6 (86.0 to 93.2)
Week 11290.6 (87.3 to 93.9)88.8 (85.1 to 92.4)
SecondaryPercentage of Participants Avoiding a Loss of ≥10 Letters From the Baseline BCVA in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥10 Letters From the Baseline BCVA in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 495.1 (92.9 to 97.4)96.2 (94.3 to 98.2)
Week 896.0 (94.0 to 98.0)96.9 (95.1 to 98.7)
Week 1296.3 (94.4 to 98.3)95.5 (93.3 to 97.7)
Week 1695.1 (92.8 to 97.4)92.6 (89.9 to 95.4)
Week 2093.9 (91.3 to 96.5)92.7 (89.9 to 95.4)
Week 2494.3 (91.7 to 96.9)94.4 (91.9 to 96.9)
Week 2893.5 (90.8 to 96.2)94.9 (92.3 to 97.4)
Week 3292.5 (89.6 to 95.3)92.9 (89.9 to 95.8)
Week 3693.2 (90.3 to 96.0)91.7 (88.6 to 94.7)
Week 4092.2 (89.2 to 95.2)91.8 (88.8 to 94.8)
Week 4492.3 (89.4 to 95.3)90.9 (87.7 to 94.2)
Week 4891.5 (88.3 to 94.6)91.5 (88.3 to 94.7)
Week 5291.7 (88.6 to 94.7)91.1 (87.8 to 94.4)
Week 5692.3 (89.3 to 95.3)90.4 (87.0 to 93.8)
Week 6090.7 (87.5 to 94.0)88.5 (85.0 to 92.1)
Week 6491.3 (88.0 to 94.6)90.3 (87.0 to 93.7)
Week 6892.2 (89.2 to 95.3)90.3 (86.9 to 93.7)
Week 7289.6 (86.2 to 93.1)88.1 (84.6 to 91.7)
Week 7689.2 (85.6 to 92.7)88.0 (84.3 to 91.8)
Week 8089.3 (85.7 to 92.9)86.4 (82.6 to 90.2)
Week 8489.0 (85.5 to 92.5)86.9 (83.2 to 90.7)
Week 8889.2 (85.7 to 92.7)85.2 (81.2 to 89.3)
Week 9287.7 (83.8 to 91.6)86.3 (82.4 to 90.1)
Week 9687.8 (84.0 to 91.5)85.7 (81.6 to 89.8)
Week 10088.6 (84.9 to 92.3)86.1 (82.1 to 90.1)
Week 10487.6 (83.7 to 91.5)85.3 (81.3 to 89.4)
Week 10885.2 (81.1 to 89.4)87.3 (83.4 to 91.2)
Week 11284.7 (80.5 to 88.9)84.2 (79.9 to 88.5)
SecondaryPercentage of Participants Avoiding a Loss of ≥5 Letters From the Baseline BCVA in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥5 Letters From the Baseline BCVA in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 490.5 (87.4 to 93.6)90.6 (87.5 to 93.6)
Week 892.3 (89.6 to 95.1)90.6 (87.5 to 93.7)
Week 1292.2 (89.4 to 95.1)88.8 (85.4 to 92.1)
Week 1690.4 (87.3 to 93.6)87.4 (83.8 to 90.9)
Week 2089.3 (85.9 to 92.7)87.1 (83.5 to 90.7)
Week 2489.1 (85.6 to 92.6)88.8 (85.3 to 92.3)
Week 2888.2 (84.6 to 91.9)90.2 (86.7 to 93.6)
Week 3287.0 (83.3 to 90.7)85.8 (81.9 to 89.6)
Week 3688.3 (84.7 to 91.9)86.7 (82.9 to 90.4)
Week 4086.8 (83.1 to 90.6)87.4 (83.7 to 91.1)
Week 4485.2 (81.3 to 89.2)85.3 (81.2 to 89.4)
Week 4885.6 (81.6 to 89.6)83.5 (79.3 to 87.7)
Week 5284.8 (80.7 to 88.9)85.5 (81.4 to 89.6)
Week 5684.4 (80.4 to 88.5)83.7 (79.4 to 88.0)
Week 6081.5 (77.0 to 85.9)84.5 (80.4 to 88.6)
Week 6487.8 (84.0 to 91.7)85.3 (81.3 to 89.4)
Week 6885.0 (80.9 to 89.1)87.0 (83.1 to 90.9)
Week 7284.2 (80.0 to 88.3)81.1 (76.6 to 85.6)
Week 7683.5 (79.1 to 87.8)83.3 (78.9 to 87.7)
Week 8081.0 (76.3 to 85.6)81.9 (77.5 to 86.4)
Week 8482.6 (78.2 to 86.9)81.8 (77.4 to 86.3)
Week 8880.8 (76.2 to 85.4)78.8 (74.1 to 83.6)
Week 9281.7 (77.1 to 86.3)79.2 (74.5 to 83.9)
Week 9682.1 (77.6 to 86.6)78.1 (73.2 to 83.0)
Week 10081.7 (77.1 to 86.3)80.1 (75.4 to 84.8)
Week 10479.6 (74.7 to 84.4)80.5 (75.8 to 85.1)
Week 10879.7 (74.9 to 84.4)80.7 (75.9 to 85.4)
Week 11278.6 (73.7 to 83.4)78.9 (74.1 to 83.7)
SecondaryPercentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, average of Weeks 40, 44, and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 4824.3 (19.5 to 29.1)21.3 (16.8 to 25.7)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: 3.0 · 95% CI -3.6 to 9.5The treatment difference in CMH weighted percentage of participants gaining ≥15 letters or achieving BCVA ≥84 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
SecondaryPercentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 411.0 (7.7 to 14.3)8.1 (5.3 to 10.9)
Week 816.3 (12.3 to 20.2)11.1 (7.8 to 14.4)
Week 1220.4 (16.2 to 24.7)14.9 (11.2 to 18.6)
Week 1620.5 (16.3 to 24.8)17.3 (13.4 to 21.3)
Week 2022.4 (17.9 to 26.9)17.7 (13.5 to 21.8)
Week 2425.5 (20.5 to 30.5)19.1 (14.7 to 23.4)
Week 2825.7 (20.8 to 30.5)20.0 (15.5 to 24.5)
Week 3227.3 (22.4 to 32.3)21.9 (17.3 to 26.5)
Week 3627.2 (22.1 to 32.2)23.7 (19.0 to 28.4)
Week 4026.0 (21.0 to 30.9)21.4 (16.8 to 25.9)
Week 4426.5 (21.5 to 31.6)22.8 (18.1 to 27.5)
Week 4824.9 (20.0 to 29.8)27.6 (22.5 to 32.6)
Week 5225.0 (20.1 to 30.0)23.8 (19.0 to 28.7)
Week 5626.4 (21.4 to 31.5)24.4 (19.7 to 29.1)
Week 6025.2 (20.2 to 30.2)22.7 (18.1 to 27.4)
Week 6424.2 (19.1 to 29.3)25.6 (20.6 to 30.5)
Week 6827.5 (22.2 to 32.8)24.3 (19.4 to 29.2)
Week 7226.1 (21.0 to 31.2)24.2 (19.4 to 29.0)
Week 7627.6 (22.2 to 32.9)23.6 (18.8 to 28.5)
Week 8024.1 (18.9 to 29.3)25.9 (20.9 to 31.0)
Week 8426.2 (21.0 to 31.4)23.8 (19.0 to 28.7)
Week 8829.4 (24.0 to 34.7)25.0 (19.9 to 30.0)
Week 9227.7 (22.2 to 33.1)27.3 (22.1 to 32.6)
Week 9628.0 (22.6 to 33.3)26.7 (21.7 to 31.8)
Week 10027.3 (22.0 to 32.7)24.4 (19.5 to 29.3)
Week 10427.9 (22.5 to 33.3)23.9 (18.9 to 28.8)
Week 10827.3 (21.9 to 32.6)24.2 (19.3 to 29.1)
Week 11226.9 (21.6 to 32.1)25.5 (20.4 to 30.6)
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\<69 letters vs. ≥69 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, average of Weeks 40, 44, and 48
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 4856.4 (51.5 to 61.4)57.0 (51.9 to 62.1)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: -0.5 · 95% CI -7.7 to 6.6The treatment difference in CMH weighted percentage of participants achieving BCVA ≥69 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\<69 letters vs. ≥69 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 452.8 (48.4 to 57.2)50.5 (46.4 to 54.7)
Week 854.5 (49.9 to 59.1)50.7 (46.3 to 55.1)
Week 1258.3 (53.7 to 62.9)53.4 (48.8 to 58.0)
Week 1660.4 (55.6 to 65.2)53.7 (49.1 to 58.3)
Week 2059.5 (54.6 to 64.5)54.4 (49.6 to 59.1)
Week 2459.4 (54.3 to 64.5)54.4 (49.4 to 59.4)
Week 2857.5 (52.4 to 62.6)59.0 (53.8 to 64.1)
Week 3257.7 (52.7 to 62.8)58.0 (52.8 to 63.1)
Week 3659.7 (54.8 to 64.7)59.6 (54.5 to 64.7)
Week 4057.5 (52.4 to 62.7)58.0 (52.8 to 63.1)
Week 4459.9 (54.8 to 65.0)59.4 (54.1 to 64.7)
Week 4858.9 (53.7 to 64.1)58.1 (52.7 to 63.6)
Week 5261.0 (55.8 to 66.1)57.4 (52.0 to 62.9)
Week 5659.0 (53.8 to 64.2)55.9 (50.5 to 61.3)
Week 6057.9 (52.4 to 63.4)56.8 (51.4 to 62.2)
Week 6462.5 (57.1 to 67.9)57.7 (52.3 to 63.0)
Week 6861.0 (55.6 to 66.4)59.3 (54.0 to 64.6)
Week 7259.5 (54.0 to 65.0)57.3 (52.0 to 62.6)
Week 7658.4 (52.9 to 63.9)55.3 (49.9 to 60.6)
Week 8056.8 (51.2 to 62.4)55.5 (50.1 to 60.9)
Week 8457.6 (52.1 to 63.1)58.0 (52.6 to 63.3)
Week 8859.1 (53.5 to 64.8)54.1 (48.5 to 59.7)
Week 9258.6 (52.9 to 64.2)57.8 (52.3 to 63.2)
Week 9659.3 (53.7 to 64.9)58.3 (52.6 to 64.0)
Week 10058.1 (52.5 to 63.8)57.4 (51.9 to 63.0)
Week 10459.8 (54.2 to 65.5)58.0 (52.4 to 63.6)
Week 10856.4 (50.7 to 62.1)56.4 (50.9 to 62.0)
Week 11256.3 (50.4 to 62.2)54.3 (48.6 to 59.9)
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, average of Weeks 40, 44, and 48
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 486.4 (3.7 to 9.1)6.9 (4.2 to 9.5)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Difference in cmh weighted percentage: -0.5 · 95% CI -4.2 to 3.3The treatment difference in CMH weighted percentage of participants with BCVA ≤38 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 45.5 (3.2 to 7.9)5.5 (3.2 to 7.7)
Week 85.8 (3.4 to 8.3)5.9 (3.6 to 8.2)
Week 124.6 (2.5 to 6.8)5.6 (3.3 to 7.9)
Week 165.8 (3.5 to 8.2)6.3 (3.9 to 8.8)
Week 205.9 (3.5 to 8.4)6.9 (4.3 to 9.5)
Week 244.3 (2.0 to 6.6)5.9 (3.4 to 8.5)
Week 285.4 (3.0 to 7.9)5.2 (2.8 to 7.7)
Week 326.1 (3.5 to 8.7)6.8 (4.2 to 9.4)
Week 366.4 (3.7 to 9.1)6.7 (4.1 to 9.3)
Week 407.1 (4.3 to 9.9)8.1 (5.3 to 11.0)
Week 447.0 (4.1 to 9.9)6.7 (4.0 to 9.3)
Week 487.4 (4.4 to 10.4)7.8 (4.9 to 10.7)
Week 528.1 (5.0 to 11.1)9.4 (6.3 to 12.6)
Week 566.3 (3.6 to 9.0)7.6 (4.7 to 10.5)
Week 606.9 (4.0 to 9.8)8.7 (5.6 to 11.7)
Week 647.8 (4.6 to 11.0)9.1 (6.0 to 12.3)
Week 687.6 (4.5 to 10.7)9.3 (6.2 to 12.5)
Week 728.6 (5.4 to 11.8)10.7 (7.5 to 13.9)
Week 767.9 (4.7 to 11.1)10.8 (7.5 to 14.2)
Week 808.8 (5.5 to 12.0)10.6 (7.2 to 13.9)
Week 847.7 (4.6 to 10.8)11.0 (7.8 to 14.2)
Week 889.5 (6.1 to 12.9)11.7 (8.3 to 15.0)
Week 929.0 (5.6 to 12.5)12.4 (9.0 to 15.7)
Week 968.6 (5.3 to 12.0)11.7 (8.2 to 15.1)
Week 1008.3 (5.0 to 11.5)11.9 (8.4 to 15.4)
Week 1049.4 (6.0 to 12.9)11.7 (8.3 to 15.1)
Week 1087.7 (4.5 to 10.9)10.4 (7.1 to 13.7)
Week 1128.2 (4.9 to 11.5)11.8 (8.3 to 15.2)
SecondaryPercentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 48

Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 48. The treatment interval at a given visit is defined as the treatment interval decision followed at that visit. The 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 48
Percentage of participantsArm A: Faricimab
Once Every 8 Weeks20.3 (15.9 to 24.8)
Once Every 12 Weeks34.0 (28.7 to 39.2)
Once Every 16 Weeks45.7 (40.2 to 51.2)
SecondaryPercentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 60

Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 60. The treatment interval at a given visit is defined as the treatment interval decision followed at that visit. The 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Week 60
Reported as:
Number · Percentage of participants
Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 60
Percentage of participantsArm A: Faricimab
Once Every 8 Weeks20.2 (15.7 to 24.7)
Once Every 12 Weeks33.4 (28.1 to 38.8)
Once Every 16 Weeks46.4 (40.7 to 52.0)
SecondaryPercentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 112

Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 112. Treatment interval at a given visit is defined as the treatment interval decision followed at that visit. Treatment interval at Week 112 is calculated using data recorded at Week 108. The 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Weeks 108 and 112
Reported as:
Number · Percentage of participants
Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 112
Percentage of participantsArm A: Faricimab
Once Every 8 Weeks25.8 (20.6 to 31.0)
Once Every 12 Weeks15.1 (10.9 to 19.4)
Once Every 16 Weeks59.0 (53.2 to 64.9)
SecondaryNumber of Study Drug Injections Received in the Study Eye Through Week 48
Time frame:
From Baseline through Week 48
Reported as:
Median · Injections
Number of Study Drug Injections Received in the Study Eye Through Week 48
InjectionsArm A: FaricimabArm B: Aflibercept
Number of Study Drug Injections Received in the Study Eye Through Week 486.0 (1 to 8)8.0 (1 to 8)
SecondaryNumber of Study Drug Injections Received in the Study Eye Through Week 60
Time frame:
From Baseline through Week 60
Reported as:
Median · Injections
Number of Study Drug Injections Received in the Study Eye Through Week 60
InjectionsArm A: FaricimabArm B: Aflibercept
Number of Study Drug Injections Received in the Study Eye Through Week 607.0 (1 to 10)9.0 (1 to 9)
SecondaryNumber of Study Drug Injections Received in the Study Eye Through Week 108
Time frame:
From Baseline through Week 108
Reported as:
Median · Injections
Number of Study Drug Injections Received in the Study Eye Through Week 108
InjectionsArm A: FaricimabArm B: Aflibercept
Number of Study Drug Injections Received in the Study Eye Through Week 10810.0 (1 to 16)15.0 (1 to 15)
SecondaryChange From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 40, 44, and 48

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (\<33 letters and ≥33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
From Baseline through Week 48
Reported as:
Mean · microns
Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 40, 44, and 48
micronsArm A: FaricimabArm B: Aflibercept
Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 40, 44, and 48-136.8 (-142.6 to -131.0)-129.4 (-135.2 to -123.5)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Adjusted mean difference: -7.4 · 95% CI -15.7 to 0.8The treatment difference in adjusted means of change from baseline CST is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept. MMRM adjustments are listed in the outcome measure description.
SecondaryChange From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 52, 56, and 60

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (\<33 letters and ≥33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
From Baseline through Week 60
Reported as:
Mean · microns
Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 52, 56, and 60
micronsArm A: FaricimabArm B: Aflibercept
Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 52, 56, and 60-134.5 (-140.5 to -128.6)-135.5 (-141.5 to -129.6)
Statistical analysis
  • Arm A: Faricimab vs Arm B: Aflibercept · Adjusted mean difference: 1.0 · 95% CI -7.4 to 9.4The treatment difference in adjusted means of change from baseline CST is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept. MMRM adjustments are listed in the outcome measure description.
SecondaryChange From Baseline in Central Subfield Thickness in the Study Eye Over Time

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (\<33 letters and ≥33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112
Reported as:
Mean · microns
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time
micronsArm A: FaricimabArm B: Aflibercept
Week 4-131.7 (-137.9 to -125.4)-116.3 (-122.5 to -110.1)
Week 8-142.6 (-148.1 to -137.2)-131.8 (-137.2 to -126.3)
Week 12-149.0 (-154.1 to -143.9)-136.1 (-141.2 to -131.1)
Week 16-148.7 (-155.1 to -142.3)-110.4 (-116.8 to -104.0)
Week 20-132.9 (-139.2 to -126.6)-136.1 (-142.4 to -129.8)
Week 24-128.8 (-135.9 to -121.8)-115.5 (-122.6 to -108.5)
Week 28-129.1 (-135.5 to -122.8)-132.5 (-139.0 to -126.1)
Week 32-142.7 (-150.2 to -135.2)-114.5 (-122.0 to -107.0)
Week 36-132.8 (-138.9 to -126.7)-139.1 (-145.2 to -133.1)
Week 40-140.8 (-148.0 to -133.7)-123.9 (-131.0 to -116.7)
Week 44-133.9 (-139.9 to -128.0)-142.4 (-148.3 to -136.4)
Week 48-138.1 (-145.1 to -131.2)-126.0 (-132.9 to -119.1)
Week 52-139.9 (-146.2 to -133.6)-139.6 (-145.9 to -133.3)
Week 56-140.4 (-147.4 to -133.3)-125.9 (-133.0 to -118.9)
Week 60-124.1 (-131.1 to -117.1)-143.5 (-150.4 to -136.5)
Week 64-145.4 (-152.4 to -138.4)-127.8 (-134.7 to -120.9)
Week 68-137.5 (-144.0 to -130.9)-142.8 (-149.4 to -136.3)
Week 72-139.7 (-147.2 to -132.3)-132.0 (-139.4 to -124.7)
Week 76-135.3 (-142.2 to -128.3)-142.8 (-149.8 to -135.9)
Week 80-146.7 (-154.3 to -139.0)-132.1 (-139.7 to -124.5)
Week 84-141.7 (-148.4 to -135.0)-143.2 (-149.9 to -136.6)
Week 88-143.9 (-150.7 to -137.2)-139.3 (-146.0 to -132.6)
Week 92-144.8 (-151.1 to -138.4)-148.5 (-154.7 to -142.2)
Week 96-147.6 (-154.6 to -140.5)-139.7 (-146.7 to -132.8)
Week 100-145.7 (-152.7 to -138.7)-147.1 (-153.9 to -140.2)
Week 104-147.7 (-154.6 to -140.8)-143.4 (-150.2 to -136.6)
Week 108-141.7 (-148.5 to -134.8)-151.0 (-157.7 to -144.2)
Week 112-150.1 (-157.1 to -143.1)-144.3 (-151.3 to -137.4)
SecondaryPercentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time

Intraretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 millimetre \[mm\]). The weighted estimates of the percentage of participants with absence of intraretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 489.2 (86.0 to 92.4)85.2 (81.6 to 88.8)
Week 887.5 (84.1 to 90.9)84.3 (80.6 to 88.1)
Week 1289.3 (86.1 to 92.5)85.4 (81.8 to 89.0)
Week 1689.2 (86.0 to 92.5)76.3 (71.8 to 80.8)
Week 2082.4 (78.3 to 86.5)83.4 (79.5 to 87.3)
Week 2480.5 (75.9 to 85.0)77.7 (73.0 to 82.4)
Week 2876.9 (72.3 to 81.4)85.3 (81.3 to 89.2)
Week 3286.8 (83.1 to 90.6)79.1 (74.6 to 83.7)
Week 3679.9 (75.5 to 84.3)83.5 (79.4 to 87.6)
Week 4082.1 (77.7 to 86.5)77.2 (72.5 to 81.9)
Week 4475.5 (70.6 to 80.3)84.9 (80.7 to 89.1)
Week 4882.1 (77.7 to 86.5)74.4 (69.4 to 79.5)
Week 5283.1 (78.8 to 87.4)85.0 (80.9 to 89.1)
Week 5684.9 (80.8 to 89.1)80.3 (75.8 to 84.9)
Week 6072.9 (67.9 to 77.9)82.3 (77.9 to 86.7)
Week 10480.0 (75.2 to 84.8)80.7 (76.1 to 85.4)
Week 10877.8 (72.9 to 82.7)84.7 (80.5 to 88.9)
Week 11282.3 (77.7 to 86.9)76.2 (71.0 to 81.3)
SecondaryPercentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time

Subretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants with absence of subretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 467.8 (62.9 to 72.7)58.8 (53.7 to 64.0)
Week 884.5 (80.6 to 88.4)76.4 (71.9 to 81.0)
Week 1287.2 (83.6 to 90.8)78.5 (74.1 to 82.9)
Week 1689.6 (86.3 to 92.9)59.9 (54.6 to 65.2)
Week 2075.1 (70.3 to 79.9)76.3 (71.6 to 81.0)
Week 2470.8 (65.6 to 75.9)63.9 (58.4 to 69.4)
Week 2871.1 (65.9 to 76.2)78.8 (74.0 to 83.5)
Week 3282.2 (77.9 to 86.5)65.1 (59.6 to 70.6)
Week 3674.1 (69.2 to 79.1)79.9 (75.4 to 84.4)
Week 4078.5 (73.9 to 83.1)67.3 (61.9 to 72.7)
Week 4469.6 (64.3 to 74.9)78.0 (73.1 to 82.8)
Week 4875.7 (70.7 to 80.8)65.8 (60.4 to 71.1)
Week 5280.6 (76.0 to 85.2)79.9 (75.3 to 84.5)
Week 5679.0 (74.3 to 83.7)70.1 (64.7 to 75.4)
Week 6067.7 (62.2 to 73.2)77.5 (72.6 to 82.3)
Week 10479.3 (74.5 to 84.2)74.9 (69.7 to 80.1)
Week 10879.6 (74.6 to 84.6)77.4 (72.4 to 82.5)
Week 11280.9 (76.1 to 85.7)73.1 (67.7 to 78.4)
SecondaryPercentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time

Intraretinal fluid and subretinal fluid were measured using optical coherence tomography (OCT) in the central subfield (center 1 millimetre \[mm\]). The weighted estimates of the percentage of participants with absence of intraretinal and subretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 460.8 (55.7 to 66.0)49.0 (43.8 to 54.2)
Week 874.5 (69.9 to 79.2)63.1 (58.0 to 68.2)
Week 1277.4 (72.9 to 81.9)66.3 (61.4 to 71.3)
Week 1678.8 (74.4 to 83.2)44.0 (38.6 to 49.4)
Week 2064.7 (59.4 to 70.0)62.2 (56.9 to 67.4)
Week 2457.2 (51.6 to 62.9)48.9 (43.2 to 54.6)
Week 2854.8 (49.2 to 60.5)66.9 (61.5 to 72.3)
Week 3271.9 (66.8 to 77.0)51.2 (45.5 to 56.9)
Week 3659.4 (53.7 to 65.1)66.6 (61.3 to 71.9)
Week 4064.8 (59.3 to 70.3)52.1 (46.3 to 57.9)
Week 4451.4 (45.6 to 57.2)65.5 (59.8 to 71.1)
Week 4863.3 (57.6 to 68.9)47.1 (41.3 to 52.9)
Week 5268.4 (63.0 to 73.8)68.4 (63.1 to 73.8)
Week 5667.8 (62.3 to 73.3)55.3 (49.4 to 61.1)
Week 6048.6 (42.7 to 54.4)62.4 (56.7 to 68.2)
Week 10463.0 (57.0 to 68.9)59.0 (53.1 to 65.0)
Week 10860.7 (54.7 to 66.8)63.6 (57.8 to 69.4)
Week 11265.9 (60.0 to 71.8)54.5 (48.4 to 60.6)
SecondaryPercentage of Participants With Absence of Pigment Epithelial Detachment in the Study Eye Over Time

Pigment epithelial detachment was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants with absence of pigment epithelial detachment were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Pigment Epithelial Detachment in the Study Eye Over Time
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Week 45.3 (2.9 to 7.6)4.9 (2.6 to 7.2)
Week 83.5 (1.5 to 5.5)4.3 (2.1 to 6.5)
Week 122.9 (1.0 to 4.7)2.1 (0.6 to 3.7)
Week 161.6 (0.2 to 3.0)4.4 (2.2 to 6.6)
Week 202.4 (0.7 to 4.1)3.9 (1.8 to 6.1)
Week 243.3 (1.2 to 5.4)4.2 (1.9 to 6.6)
Week 282.9 (1.0 to 4.8)5.8 (3.1 to 8.5)
Week 323.4 (1.4 to 5.5)3.6 (1.4 to 5.7)
Week 364.3 (1.9 to 6.6)6.4 (3.7 to 9.2)
Week 407.8 (4.7 to 10.9)9.9 (6.5 to 13.3)
Week 443.6 (1.5 to 5.8)8.8 (5.5 to 12.2)
Week 483.4 (1.3 to 5.5)7.7 (4.6 to 10.7)
Week 522.3 (0.5 to 4.1)3.5 (1.4 to 5.7)
Week 562.6 (0.7 to 4.5)5.8 (3.0 to 8.5)
Week 604.2 (1.8 to 6.5)6.4 (3.6 to 9.2)
Week 1043.7 (1.4 to 6.0)4.9 (2.3 to 7.6)
Week 1083.1 (0.9 to 5.4)7.5 (4.2 to 10.7)
Week 1124.0 (1.6 to 6.4)8.0 (4.7 to 11.2)
SecondaryPercentage of Participants With Absence of Intraretinal Cysts in the Study Eye Over Time
Time frame:
Up to 112 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 48

The total area of the choroidal neovascularization lesion in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

Time frame:
Baseline and Week 48
Reported as:
Mean · millimetres squared (mm^2)
Change From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 48
millimetres squared (mm^2)Arm A: FaricimabArm B: Aflibercept
Change From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 480.0 ± 4.50.4 ± 4.8
SecondaryChange From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 112

The total area of the choroidal neovascularization lesion in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

Time frame:
Baseline and Week 112
Reported as:
Mean · millimetres squared (mm^2)
Change From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 112
millimetres squared (mm^2)Arm A: FaricimabArm B: Aflibercept
Change From Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 1121.2 ± 4.61.6 ± 5.0
SecondaryChange From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 48

The total area of choroidal neovascularization leakage in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

Time frame:
Baseline and Week 48
Reported as:
Mean · millimetres squared (mm^2)
Change From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 48
millimetres squared (mm^2)Arm A: FaricimabArm B: Aflibercept
Change From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 48-3.8 ± 6.9-3.0 ± 6.9
SecondaryChange From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 112

The total area of choroidal neovascularization leakage in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

Time frame:
Baseline and Week 112
Reported as:
Mean · millimetres squared (mm^2)
Change From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 112
millimetres squared (mm^2)Arm A: FaricimabArm B: Aflibercept
Change From Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 112-5.4 ± 5.7-5.0 ± 6.4
SecondaryPercentage of Participants With at Least One Adverse Event

This analysis of adverse events (AEs) includes both ocular and non-ocular (systemic) AEs. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. AEs of special interest included the following: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law; Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

Time frame:
From first dose of study drug through end of study (up to 112 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Adverse Event
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Adverse Event (AE)88.389.3
Serious AE (SAE)24.027.7
AE Leading to Withdrawal from Study Treatment3.62.7
AE of Special Interest (AESI)4.86.8
SecondaryPercentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye

This analysis of adverse events (AEs) only includes ocular AEs, which are categorized as having occurred either in the study eye or the fellow eye. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

Time frame:
From first dose of study drug through end of study (up to 112 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Study Eye: Adverse Event (AE)55.056.5
Study Eye: Serious AE (SAE)4.23.9
Study Eye: AE Leading to Withdrawal from Treatment1.80.6
Study Eye: Treatment-related AE4.22.7
Study Eye: Treatment-related SAE1.20.0
Study Eye: AE of Special Interest (AESI)3.63.9
Study Eye: AESI, Drop in VA Score ≥30 Letters2.73.0
Study Eye: AESI, Associated with Severe IOI0.30.3
Study Eye: AESI, Intervention Req. to Prevent Permanent Vision Loss0.60.6
Fellow Eye: AE39.344.3
Fellow Eye: SAE1.23.3
Fellow Eye: AESI1.23.0
Fellow Eye: AESI, Drop in VA Score ≥30 Letters0.92.1
Fellow Eye: AESI, Intervention Req. to Prevent Permanent Vision Loss0.30.9
SecondaryPercentage of Participants With at Least One Non-Ocular Adverse Event

This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

Time frame:
From first dose of study drug through end of study (up to 112 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Non-Ocular Adverse Event
Percentage of participantsArm A: FaricimabArm B: Aflibercept
Adverse Event (AE)75.772.9
Serious AE (SAE)19.822.6
AE Leading to Withdrawal from Study Treatment1.82.1
AE of Special Interest (AESI)0.00.3
SecondaryPlasma Concentration of Faricimab Over Time

Faricimab concentration in plasma was determined using a validated immunoassay method.

Time frame:
Pre-dose at Baseline, Weeks 4, 16, 20, 48, 76, and 112
Reported as:
Mean · micrograms per millilitre (μg/mL)
Plasma Concentration of Faricimab Over Time
micrograms per millilitre (μg/mL)Arm A: Faricimab
Baseline0.0000 ± 0.0005
Week 40.0288 ± 0.0194
Week 160.0337 ± 0.0266
Week 200.0044 ± 0.0062
Week 480.0139 ± 0.0175
Week 760.0057 ± 0.0109
Week 1120.0099 ± 0.0140
SecondaryPercentage of Participants Who Tested Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study

Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The percentage of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period.

Time frame:
Pre-dose at Baseline, Weeks 4, 20, 48, 76, and 112
Reported as:
Number · Percentage of participants
Percentage of Participants Who Tested Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study
Percentage of participantsArm A: Faricimab
Total Treatment-Emergent ADA-Positive11.5
Treatment-Induced ADA-Positive11.2
Treatment-Boosted ADA-Positive0.3

Adverse events

Collected over From first dose of study drug through end of study (up to 112 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Faricimab13/333 (3.9%)80/333 (24%)211/333 (63.4%)
Arm B: Aflibercept7/336 (2.1%)93/336 (27.7%)200/336 (59.5%)
Most frequent serious events
Showing 10 of 163
Most frequent serious events
EventArm A: FaricimabArm B: Aflibercept
Neovascular age-related macular degenerationEye disorders1/3339/336
PneumoniaInfections and infestations6/3335/336
Atrial fibrillationCardiac disorders5/3334/336
COVID-19Infections and infestations5/3334/336
CataractEye disorders2/3335/336
Cardiac failure congestiveCardiac disorders3/3331/336
EndophthalmitisInfections and infestations3/3330/336
Femur fractureInjury, poisoning and procedural complications1/3333/336
DehydrationMetabolism and nutrition disorders0/3333/336
DizzinessNervous system disorders0/3333/336
Most frequent other events
Showing 10 of 13
Most frequent other events
EventArm A: FaricimabArm B: Aflibercept
Neovascular age-related macular degenerationEye disorders65/33363/336
Conjunctival haemorrhageEye disorders36/33333/336
CataractEye disorders27/33336/336
NasopharyngitisInfections and infestations23/33335/336
Urinary tract infectionInfections and infestations26/33323/336
HypertensionVascular disorders24/33313/336
Dry eyeEye disorders18/33324/336
Vitreous floatersEye disorders23/33312/336
ArthralgiaMusculoskeletal and connective tissue disorders22/33319/336
Vitreous detachmentEye disorders19/33321/336

Baseline characteristics

Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization.

Age, Continuous
Age, Continuous(Years)Arm A: FaricimabArm B: AfliberceptTotal
Mean75.9 ± 8.676.7 ± 8.876.3 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: FaricimabArm B: AfliberceptTotal
Female191211402
Male143126269
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: FaricimabArm B: AfliberceptTotal
Hispanic or Latino262652
Not Hispanic or Latino303308611
Unknown or Not Reported538
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A: FaricimabArm B: AfliberceptTotal
White303302605
Asian262854
Black or African American033
American Indian or Alaska Native123
Multiple101
Unknown325
Region of Enrollment
Region of Enrollment(Participants)Arm A: FaricimabArm B: AfliberceptTotal
United States and Canada182184366
Asia262652
Rest of the World126127253
Number of Participants by the Eye (Right or Left) Chosen as the Study Eye
Number of Participants by the Eye (Right or Left) Chosen as the Study Eye(Participants)Arm A: FaricimabArm B: AfliberceptTotal
Right Eye166178344
Left Eye168159327
Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye
Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye(ETDRS Letters)Arm A: FaricimabArm B: AfliberceptTotal
Mean61.3 ± 12.561.5 ± 12.961.4 ± 12.7
Number of Participants by the BCVA Letter Score Categories in the Study Eye
Number of Participants by the BCVA Letter Score Categories in the Study Eye(Participants)Arm A: FaricimabArm B: AfliberceptTotal
≥74 Letters475299
73 to 55 Letters200201401
≤54 Letters8784171

2 further baseline measures are reported on the registry.

08

Study locations

161 sites
  • Retinal Research Institute, LLC
    Phoenix, Arizona 85014, United States
  • Barnet Dulaney Perkins Eye Center
    Phoenix, Arizona 85016, United States
  • Retina Associates Southwest PC
    Tucson, Arizona 85704, United States
  • Retinal Diagnostic Center
    Campbell, California 95008, United States
  • The Retina Partners
    Encino, California 91436, United States
  • Jacobs Retina center at the Shiley eye Institute UCSD
    La Jolla, California 92093, United States
  • South Coast Retina Center
    Long Beach, California 90807, United States
  • Southern CA Desert Retina Cons
    Palm Desert, California 92211, United States
  • California Eye Specialists Medical group Inc.
    Pasadena, California 91107, United States
  • Retina Consultants, San Diego
    Poway, California 92064, United States
  • Retina Consultants of Southern California
    Redlands, California 92373, United States
  • University of California, Davis, Eye Center
    Sacramento, California 95817, United States
  • Retina Consultants of Southern
    Colorado Springs, Colorado 80909, United States
  • Retina Group of New England
    New London, Connecticut 06320, United States
  • Rand Eye
    Deerfield Beach, Florida 33064, United States
  • Florida Eye Associates
    Melbourne, Florida 32901, United States
  • Retina Specialty Institute
    Pensacola, Florida 32503, United States
  • Fort Lauderdale Eye Institute
    Plantation, Florida 33324, United States
  • Retina Vitreous Assoc of FL
    St. Petersburg, Florida 33711, United States
  • Northwestern Medical Group/Northwestern University
    Chicago, Illinois 60611, United States
  • Retina Associates
    Lenexa, Kansas 66215, United States
  • Johns Hopkins Med
    Baltimore, Maryland 21287, United States
  • Retina Group of Washington
    Chevy Chase, Maryland 20815, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Associated Retinal Consultants
    Grand Rapids, Michigan 49546, United States
  • Midwest Vision Research Foundation
    Chesterfield, Missouri 63017, United States
  • Retina Associates of St. Louis
    Florissant, Missouri 63031, United States
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
  • NJ Retina
    Edison, New Jersey 08820, United States
  • Retina Associates of NJ
    Teaneck, New Jersey 07666, United States
  • Long Is. Vitreoretinal Consult
    Great Neck, New York 11021, United States
  • Ophthalmic Cons of Long Island
    Oceanside, New York 11572, United States
  • Retina Assoc of Western NY
    Rochester, New York 14620, United States
  • The Retina Consultants
    Slingerlands, New York 12159, United States
  • Retina Vit Surgeons/Central NY
    Syracuse, New York 13224, United States
  • Western Carolina Retinal Associate PA
    Asheville, North Carolina 28803, United States
  • Char Eye Ear &Throat Assoc
    Charlotte, North Carolina 28210, United States
  • Graystone Eye
    Hickory, North Carolina 28602, United States
  • Carolina Eye Associates
    Southern Pines, North Carolina 28387, United States
  • Cincinnati Eye Institute
    Cincinnati, Ohio 45242, United States
  • Retina Northwest
    Portland, Oregon 97221, United States
  • Mid Atlantic Retina - Wills Eye Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Charleston Neuroscience Inst
    Ladson, South Carolina 29456, United States
  • Black Hills Eye Institute
    Rapid City, South Dakota 57701, United States
  • Charles Retina Institute
    Germantown, Tennessee 38138, United States
  • Tennessee Retina PC.
    Nashville, Tennessee 37203, United States
  • Texas Retina Associates
    Dallas, Texas 75231, United States
  • Retina & Vitreous of Texas
    Houston, Texas 77025, United States
  • Retina Consultants of Texas
    Houston, Texas 77030, United States
  • Valley Retina Institute P.A.
    McAllen, Texas 78503, United States
  • Rocky Mountain Retina
    Salt Lake City, Utah 84107, United States
  • Spokane Eye Clinical Research
    Spokane, Washington 99204, United States
  • Calgary Retina Consultants
    Calgary, Alberta T2J 0C8, Canada
  • University of British Columbia - Vancouver Coastal Health Authority
    Vancouver, British Columbia V5Z 1M9, Canada
  • Ivey Eye Institute
    London, Ontario N6A 4V2, Canada
  • University of Ottawa Eye Institute
    Ottawa, Ontario K1H 8L5, Canada
  • Retina Institute of Ottawa
    Ottawa, Ontario K2B 7E9, Canada
  • Toronto Retina Institute
    Toronto, Ontario M3C 0G9, Canada
  • Unity Health Toronto
    Toronto, Ontario M5C 2T2, Canada
  • Institut De L'Oeil Des Laurentides
    Boisbriand, Quebec J7H 1S6, Canada
  • Michel Giunta Clinique Medical
    Sherbrooke, Quebec J1G 2V4, Canada
  • Universitätsklinikum Freiburg, Klinik für Augenheilkunde
    Freiburg im Breisgau, 79106, Germany
  • Universitätsklinik Heidelberg
    Heidelberg, 69120, Germany
  • Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
  • Budapest Retina Associates Kft.
    Budapest, 1133, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Ganglion Medial Center
    Pécs, 7621, Hungary
  • Zala Megyei Kórház
    Zalaegerszeg, 8900, Hungary
  • Rambam Medical Center
    Haifa, 3109601, Israel
  • Hadassah MC
    Jerusalem, 91120, Israel
  • Rabin MC
    Petah Tikva, 4941492, Israel
  • Kaplan Medical Center
    Rehovot, 7660101, Israel
  • Tel Aviv Sourasky MC
    Tel Aviv, 6423906, Israel
  • Ospedale Clinicizzato SS Annunziata
    Chieti, Abruzzo 66100, Italy
  • Fondazione G.B. Bietti Per Lo Studio E La Ricerca in Oftalmologia-Presidio Ospedaliero Britannico
    Rome, Lazio 00198, Italy
  • Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico-Clinica Regina Elena
    Milan, Lombardy 20100, Italy
  • Azienda Ospedaliera di Perugia Ospedale S. Maria Della Misericordia
    Perugia, Umbria 06129, Italy
  • Chukyo Hospital
    Aichi, 457-8510, Japan
  • Nagoya University Hospital
    Aichi, 466-8560, Japan
  • Nagoya City University Hospital
    Aichi, 467-8602, Japan
  • Aichi Medical University Hospital
    Aichi, 480-1195, Japan
  • Daiyukai Daiichi Hospital
    Aichi, 491-8551, Japan
  • Chiba University Hospital
    Chiba, 260-8677, Japan
  • Toho University Sakura Medical Center
    Chiba, 285-8741, Japan
  • Hayashi Eye Hospital
    Fukuoka, 812-0011, Japan
  • Kurume University Hospital
    Fukuoka, 830-0011, Japan
  • Southern TOHOKU Eye Clinic
    Fukushima, 963-8052, Japan
  • Sapporo City General Hospital
    Hokkaido, 060-8604, Japan
  • Hokkaido University Hospital
    Hokkaido, 060-8648, Japan
  • Asahikawa Medical University Hospital
    Hokkaido, 078-8510, Japan
  • Hyogo Prefectural Amagasaki General Medical Center (Hyogo AGMC)
    Hyōgo, 660-8550, Japan
  • Hyogo Medical University Hospital
    Hyōgo, 663-8501, Japan
  • Kozawa eye hospital and diabetes center
    Ibaraki, 310-0845, Japan
  • Kagawa University Hospital
    Kagawa, 761-0793, Japan
  • Kagoshima University Hospital
    Kagoshima, 890-8520, Japan
  • Ideta Eye Hospital
    Kumamoto, 860-0027, Japan
  • Kyoto University Hospital
    Kyoto, 606-8507, Japan
  • Mie University Hospital
    Mie, 514-8507, Japan
  • Fukushima Medical University Hospital
    Miyagi, 960-1295, Japan
  • University of Miyazaki Hospital
    Miyazaki, 889-1692, Japan

Showing the first 100 of 161 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology. 2024 Aug;131(8):914-926. doi: 10.1016/j.ophtha.2024.02.014. Epub 2024 Feb 19. PubMed 38382813 ↗
  • Pitcher JD 3rd, Koh AHC, Tan CS, Vakharia P, Dagincourt N, Patel S, Yang M, Margaron P, Gallego-Pinazo R. Rapid Fluid Resolution and Durability With Faricimab in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2026 Mar 1;144(3):269-272. doi: 10.1001/jamaophthalmol.2025.6365. PubMed 41712218 ↗
  • Takahashi K, Cheung CMG, Iida T, Lai TYY, Ohji M, Yanagi Y, Kawano M, Ohsawa S, Suzuki T, Kotecha A, Lin H, Patel V, Swaminathan B, Lee WK; TENAYA, LUCERNE Investigators. Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials. Graefes Arch Clin Exp Ophthalmol. 2023 Nov;261(11):3125-3137. doi: 10.1007/s00417-023-06071-8. Epub 2023 Jun 9. PubMed 37294433 ↗
  • Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik JF, Kotecha A, Lin H, Silverman D, Swaminathan B, Willis JR, Yoon YH, Quezada-Ruiz C. TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration. Ophthalmol Sci. 2021 Nov 17;1(4):100076. doi: 10.1016/j.xops.2021.100076. eCollection 2021 Dec. PubMed 36246941 ↗
  • Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. PubMed 35085502 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Oct 2020, 20 months.

Results were first posted in May 2022, 1 year 6 months after primary completion. A results delay was requested in Sep 2021.

Of 16 phase 3 interventional studies under Wet Macular Degeneration, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 50. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2019
First posted
Jan 30, 2019
StartActual
Feb 19, 2019
Primary completionActual
Oct 26, 2020
CompletionActual
Jan 18, 2022
Results delay requested
Sep 1, 2021
Results first posted
May 4, 2022
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03823287
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 30, 2019
Start date
Feb 19, 2019
Primary completion
Oct 26, 2020
Completion
Jan 18, 2022
Results posted
May 4, 2022
Last update
Jul 23, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Faricimab

Start the discussion